

AGENDA

Thursday, June 18

7:00-8:00 AM Breakfast & Registration

8:00-8:40 AM **Welcome and Introduction**
Caitlin Grzeskowiak, PhD, Chief Research & Innovation Officer, Epilepsy Foundation
Jacqueline French, MD, Medical Director, Epilepsy Foundation and Founder & Director, Epilepsy Study Consortium
Bernice Martin Lee, Chief Executive Officer, Epilepsy Foundation
Jack Parent, MD, President, American Epilepsy Society
Alla Guekht, President, International League Against Epilepsy
Donna Walsh, Chief Executive Officer, International Bureau for Epilepsy

Session I: Preclinical

Moderator: *Jack Parent, MD, American Epilepsy Society*

8:40-8:50 AM **Epilepsy Experience Expert**
Shane Hegarty, PhD, Axonis

8:50-9:05 AM **Future Directions in NINDS Epilepsy Preclinical Research**
Brian Klein, PhD, National Institute of Neurological Disorders and Stroke

9:05-9:25 AM **Panel: Can invitro Models Replace invivo Models for Drug Discovery**
Brian Klein, PhD, National Institute of Neurological Disorders and Stroke
Karen Wilcox, PhD, University of Utah
Shane Hegarty, PhD, Axonis

9:25-9:35 AM **Q&A**

9:35-10:10 AM **Pipeline Speaker Panel**

9:35-9:40 AM **A Novel miRNA Targeting Therapeutic NMT.001 for Adult Focal Drug Resistant Epilepsy**
Ina Bruenig-Traebert, PhD, Neumirna Therapeutics

9:40-9:45 AM **A Novel Mitochondrial-Protective Antiseizure Compound for Broad-Spectrum Epilepsies**
Sherine Chan, PhD, Neuroene Therapeutics

9:45-9:50 AM **Somatostatin SSTR4 Agonists - A Novel & Differentiated Therapeutic Opportunity for Epilepsy**
Gareth Hicks, PhD, Nocicera Therapeutics

9:50-9:55 AM **Allosteric Inhibition of Phosphodiesterase 4B for Treatment of Refractory Epilepsy**
Deborah Kurrasch, PhD, Stream Neuroscience

AGENDA

9:55-10:00 AM

SEN126, A CBD Analog with Superior DMPK and Efficacy
Josh Nickols, PhD, MBA, Sensa Neuroscience

10:00-10:10 AM

Q&A

10:10-10:25 AM

Networking Break

**Session II: Proof of Principle Studies:
PPR, TMS, and RNS in Epilepsy Drug Development**
Moderator: *Claude Steriade, MD, CM, New York University*

10:25-10:45 AM

Introduction to Proof of Concept & PPR Studies
Jacqueline French, MD, Epilepsy Foundation & Epilepsy Study Consortium

10:45-11:00 AM

**Using Data from implanted Devices as a Biomarker of
Drug Response**
Dan Friedman, MD, New York University

11:00-11:15 AM

Transcranial Magnetic Stimulation (TMS)
Alexander Rotenberg, MD, PhD, Harvard Medical School

11:15-11:35 AM

Panel: What is an Optimal Proof of Concept Study?
Dan Friedman, MD, New York University
Jacqueline French, MD, Epilepsy Foundation & Epilepsy Study Consortium
Alexander Rotenberg, MD, PhD, Harvard Medical School

11:35-11:50 AM

Q&A

11:50 AM-12:30 PM

Panel: Investor Perspectives in Epilepsy
Anupam Dalal, MD, Acuta Capital Partners
Michael Fenn, PhD, Iaso Ventures
Raymond Kelleher, MD, PhD, Cormorant Asset Management
Yasmeen Rahimi, PhD, Piper Sandler
Basheer Zada, MS, EcoRI Capital

12:30-1:30 PM

Networking Lunch

Session III: Digital Solutions/Devices
Moderator: *Jennifer Hopp, MD, University of Maryland*

1:30-1:40 PM

Epilepsy Experience Expert
Andy Baskerville, Epilepsy Foundation Research Ambassador

AGENDA

1:40-2:15 PM	Pipeline Speaker Panel
1:40-1:45 PM	Making Invisible Neurological Symptoms Visible <i>Parth Amin, Eysz</i>
1:45-1:50 PM	Validated Model to Predict Anti-Seizure Medication Response in New-Onset Focal Epilepsy with Scalp EEG <i>Peter Galer, PhD, Neumarker, Inc.</i>
1:50-1:55 PM	Largest Sub-Scalp EEG Study with US Data Completed: Strong Evidence for Ultra Long-Term EEG (ULTRA) <i>Jonas Duun-Henriksen, PhD, UNEEG Medical</i>
1:55-2:00 PM	AI Driven Clinical Intelligence System for Epilepsy Care <i>Himanshu Misra, PhD, EnlitenAI</i>
2:00-2:05 PM	The Fenfluramine Patch (FFA-eTDDS) - Phase 1 First-in-Human Trial <i>Pat Kelly, MSEE, Remagine Labs</i>
2:05-2:15 PM	Q&A
2:15-2:45 PM	Pipeline Speaker Panel
2:15-2:20 PM	Cortalis Neuro: Guiding Precision for Epilepsy Neuromodulation <i>Jonathon Parker, MD, PhD, Mayo Clinic Arizona</i>
2:20-2:25 PM	Komori: Sleep, Finally Understood? <i>Dövy Paukstys, Komori Care, LLC</i>
2:25-2:30 PM	Retrospective Analysis of Theta Neurotech's Seizure Prediction Algorithm <i>Truman Pierson, Theta Neurotech</i>
2:30-2:35 PM	Wearable EEG and AI for Continuous Home Monitoring in Epilepsy <i>Oren Shriki, PhD, NeuroHelp</i>
2:35-2:45 PM	Q&A
2:45-3:00 PM	Networking Break

AGENDA

Shark Tank Competition

3:00-3:05 PM

Shark Tank Welcome

Jacqueline French, MD, Epilepsy Foundation & Epilepsy Study Consortium

3:05-3:15 PM

Shark Tank Past Winners: How have they done?

Caitlin Grzeskowiak, PhD, Epilepsy Foundation

3:15-3:25 PM

2024 Winner Update

John Terry, FMedSci, Neuronostics

3:25-3:35 PM

2024 Winner Update

Dan Friedman, MD, Neuroview

3:35-4:20 PM

Shark Tank Investment Competition

3:35-3:40 PM

Investment Shark Introductions

Moderator: *Caitlin Grzeskowiak, PhD, Epilepsy Foundation*

Investment Sharks:

Dennis Dlugos, MD, MSCE, Children's Hospital of Pennsylvania

Michael Fenn, PhD, Iaso Ventures

Danielle Hochman, Advocate

May Liang, JD, Epilepsy Foundation Board of Directors (former)

3:40-4:25 PM

Investment Shark Tank Finalist Pitches

Investment Prize Finalists:

MSCA-7136: A brain penetrant MEK inhibitor for epilepsy

Deven Sanon, Mosaica Medicines, Inc

NeuroWeaves: Chronic, Minimally-Invasive EEG

Sydney Cash, MD, PhD, FAES, Massachusetts General Hospital

EpiScalp™: Software revolutionizing epilepsy diagnosis

Andy Gotshalk, Neurologic Solutions

4:25-4:40 PM

Deliberation & Announce

2026 Shark Tank Investment Prize Winner

4:40-5:30 PM

Shark Tank Community Competition

4:40-4:45 PM

Community Shark Introductions

Moderator: *Tom Stanton, Danny Did Foundation*

Community Sharks:

Jack Parent, MD, American Epilepsy Society

Gabi Conecker, DEE-P Connections

Claude Steriade, MD, CM, New York University

Michelle Theeuwes, Epilepsy Foundation Research Ambassador

AGENDA

4:45–5:15 PM	Community Shark Tank Finalist Pitches Community Prize Finalists: Drug Repurposing for CDKL5 Deficiency Disorder: AI-Driven Target Discovery and Phase IIa Clinical Validation <i>Jainu Jogani, MS, Child's Cure Genetic Research Foundation</i> Transcranial Pulsed Current Stimulation for Drug-Resistant Epilepsy <i>Brin Freund, MD, Mayo Clinic Florida</i>
5:15-5:30 PM	Voting & Announce 2026 Shark Tank Community Prize Winner
5:30-6:00 PM	Award Presentations 2026 Epilepsy Foundation Lifetime Accelerator Award Joyce A Cramer, MS Linott Award Aisha Abdul-Razaq, MD, University of Minnesota Mahjabeen Ahmed Khan, MD, Orlando Health AES Mini Grant Kia Gilani, MD, Icahn School of Medicine at Mount Sinai
6:00 PM	Networking Reception

AGENDA

Friday, June 19

7:00-8:00 AM **Breakfast and Registration**

8:00-8:05 AM **Welcome Remarks**

Konrad Werhahn, MD, PhD, Global Medical Head of Neurology New Population Strategy UCB

Session IV: Epilepsy Devices, Data, and AI

Moderator: *Dan Friedman, MD, New York University*

8:05-8:15 AM **Epilepsy Experience Expert**

Himanshu Misra, PhD, EnlitenAI

8:15-8:30 AM **Evolving Role of AI in Wearable and Non-Wearable Devices**

Gregory Krauss, MD, Johns Hopkins University

8:30-8:45 AM **Regulatory Updates on AI**

Jay Gupta, U.S. Food and Drug Administration

8:45-9:00 AM **Innovation and AI Initiatives at the Epilepsy Foundation**

Caitlin Grzeskowiak, PhD, Epilepsy Foundation

9:00-9:15 AM **Q&A**

Session V: Pipeline for Gene Based and Cell Therapies

Moderator: *Tracy Dixon-Salazar, PhD, LGS Foundation*

9:15-9:25 AM **Epilepsy Experience Expert**

Tracy Dixon-Salazar, PhD, LGS Foundation

9:25-10:00 AM **Pipeline Speaker Panel**

9:25-9:30 AM **Rezanecel (NRTX-1001) GABAergic Interneuron Cell Therapy for Drug-Resistant Mesial Temporal Lobe Epilepsy: Clinical Update**

Jessica Roland, PhD, Neurona Therapeutics

9:30-9:35 AM **A Cell Type-Selective Gene Therapy Approach to Combating Epilepsy**

Boaz Levi, PhD, EpiCure Therapeutics

9:35-9:40 AM **Clinical Development of Zorevunersen: An Investigational ASO for Dravet Syndrome**

Ian Miller, MD, Stoke Therapeutics

AGENDA

9:40–9:45 AM	GenTLE Phase 1/2a Clinical Study of AMT-260: Preliminary Results of an Investigational Gene Therapy for Refractory MTLTLE <i>Firas Taha, MD, uniQure</i>
9:45–9:50 AM	Developing Disease Modifying Therapies for Neurogenetic Disorders <i>Yael Weiss, MD, PhD, Mahzi Therapeutics</i>
9:50–10:00 AM	Q&A
10:00–10:15 AM	Research Roundtable for Epilepsy (RRE) Recap: Natural History Control for Trials <i>Vanessa Vogel-Farley, Rare Epilepsy Network</i>
10:15–10:30 AM	Networking Break
Session VI: Pediatric Trials Moderator: <i>Dennis Dlugos, MD, MSCE, Children’s Hospital of Philadelphia</i>	
10:30–10:40 AM	Epilepsy Experience Expert <i>Rebecca Dolan, PhD, Epilepsy Foundation Research Ambassador</i>
10:40–11:10 AM	Pipeline Speaker Panel
10:40–10:45 AM	Elsunersen for Early Onset SCN2A DEE: Results from the EMBRAVE Part A Study <i>Steve Petrou, PhD, Praxis Precision Medicines</i>
10:45–10:50 AM	POLARIS Phase 1/2 Program: Interim Safety and Preliminary Efficacy Results of ETX101, a One-Time Gene Regulation Therapy, in Young Children with Dravet Syndrome <i>Joseph Sullivan, MD, FAES, Encoded Therapeutics</i>
10:50–10:55 AM	Clinical Translation of Enhanced SCN1A Splice Switching: The ASCEND Study (NCT07531745) of ION337 in Dravet Syndrome <i>Tara Crowder Skarpaas, PhD, Ionis Pharmaceuticals</i>
10:55–11:00 AM	Preclinical and Clinical Evidence Supporting Radiprodil as a Precision Therapy for GRIN-Related Neurodevelopmental Disorder (GRIN-NDD) <i>Russell Chin, MD, GRIN Therapeutics/Neurvati Neurosciences</i>
11:00–11:10 AM	Q&A

AGENDA

Session VII: Clinical Drugs

Moderator: *Roger Porter, MD, University of Pennsylvania*

11:10-11:20 AM

Epilepsy Experience Expert

Sara Stowell, MS, Epilepsy Foundation Research Ambassador

11:20-11:55 AM

Pipeline Speaker Panel

11:20-11:25 AM

BMB-101-New Hope for People with Refractory Epilepsies

Stephen Collins, MD, PhD, Bright Minds Biosciences

11:25-11:30 AM

Development of First-in-Class Oral KCC2 potentiators for the Treatment of Neurological Disorders

Shane Hegarty, PhD, Axonis Therapeutics

11:30-11:35 AM

OV329, Next Generation GABA-AT Inhibitor, initiating Phase 2 Studies

Julia Tsai, PhD, Ovid Therapeutics

11:35-11:40 AM

The Bexicaserin DEEP Clinical Development Program: Evaluating an Investigational Treatment for Seizures Associated with Developmental and Epileptic Encephalopathies (DEEs)

Tolga Uz, MD, PhD, Lundbeck

11:40-11:45 AM

Harmony Biosciences: Rare Epilepsy Portfolio Development Update

Amit Ray, MD, Harmony Biosciences

11:40-11:55 AM

Q&A

11:55 AM-1:00 PM

Networking Lunch

Session VIII: Clinical Trials

Moderator: *Jacqueline French, MD, Epilepsy Foundation & Epilepsy Study Consortium*

1:00-1:10 PM

Epilepsy Experience Expert

Alison Kukla, MPH, Partners Against Mortality in Epilepsy

1:10-1:40 PM

Panel: Access to Investigational Medicine after Randomized Trial Balancing Burden of Clinical Trial Participation - The Role of the Sponsor, Site, Coordinator and Participant

Dan Friedman, MD, New York University

Brad Galer, MD, Mosaica Medicines

Alison Kukla, MPH, Partners Against Mortality in Epilepsy

Jennie Minnick, BA, CCRP, Children's Hospital of Pennsylvania

Tolga Uz, MD, PhD, Lundbeck

AGENDA

1:40-2:10 PM	Engaging Experts: Epilepsy Foundation Research Ambassadors <i>Caitlin Grzeskowiak, PhD, Epilepsy Foundation</i> <i>Michelle Theeuwes, Epilepsy Foundation Research Ambassador</i>
2:10-2:40 PM	Networking Break
2:40-2:55 PM	Reimagining Clinical Trial Design to Increase Inclusivity <i>Claude Steriade, MD, CM, New York University</i>
2:55-3:10 PM	Research Roundtable for Epilepsy Recap: Improving Trial Efficiency <i>Wesley Kerr, MD, PhD, University of Pittsburgh</i>
3:10-3:40 PM	Q&A

Session IX: Clinical Drugs

Moderator: Wesley Kerr, MD, PhD, University of Pittsburgh

3:40-4:15 PM	Pipeline Speaker Panel
3:40-3:45 PM	QRL-101-05 Results: Phase 1 Proof-of-Mechanism Study of QRL-101 in Healthy Volunteers <i>Taylor Gray, MS, QurAlis</i>
3:45-3:50 PM	Seizure “Freedom” and Seizure Shifts <i>Kate Nichol, PhD, MBA, LivaNova</i>
3:50-3:55 PM	NPT 2042 Clinical Data Summary <i>Daryl Hochman, PhD, NeuroPro Therapeutics</i>
3:55-4:00 PM	Revolutionizing the Delivery of Rescue Medications <i>Tony Tipton, Crossject USA</i>
4:00-4:05 PM	PrevEp006, intranasal Seletacetam: From Daily Treatment to On Demand Seizure Prevention <i>Pavel Klein, MD, PrevEP, Inc.</i>
4:05-4:15 PM	Q&A

AGENDA

4:15-4:50 PM

Pipeline Speaker Panel

4:15-4:20 PM

Staccato Alprazolam Phase 3 program

Robert Roebeling, MD, UCB

4:20-4:25 PM

SPN-817 for Focal Epilepsy

Jonathan Rubin, MD, Supernus Pharmaceuticals

4:25-4:30 PM

Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults with Focal Onset Seizures (FOS)

Monica B. Dhakar, MD, Xenon Therapeutics

4:30-4:35 PM

Opakalim, a Modern Potassium Channel Activator

Jason Lerner, MD, Biohaven Pharmaceuticals

4:35-4:40 PM

RAP-219 Focal Seizure Program Update

Neal Nolan, MD, Rapport Therapeutics

4:40-4:50 PM

Q&A

4:50-5:00 PM

Concluding Remarks